This report covers the 7MM and provides an Excel-based forecast model for the Huntington’s Disease market through 2034.
The current HD treatments are used to alleviate the symptoms associated with the disease, with all of the approved drugs indicated for the management of chorea associated with HD. VMAT2 inhibitors dominated the HD market in 2024, accounting for 99.8% of sales in the 7MM. The key focus in the pipeline is on developing DMTs for HD, and huntingtin-lowering strategies are key area of development. Companies are pursuing various mechanisms to achieve this, including gene therapies, antisense oligonucleotides (ASOs), and oral therapeutics. The HD market across the 7MM was valued at $0.3 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 27.4%, reaching $3.8 billion by 2034. A key driver of growth will be the launch of seven late-stage pipeline products, including the first DMTs for HD.
The current HD treatments are used to alleviate the symptoms associated with the disease, with all of the approved drugs indicated for the management of chorea associated with HD. VMAT2 inhibitors dominated the HD market in 2024, accounting for 99.8% of sales in the 7MM. The key focus in the pipeline is on developing DMTs for HD, and huntingtin-lowering strategies are key area of development. Companies are pursuing various mechanisms to achieve this, including gene therapies, antisense oligonucleotides (ASOs), and oral therapeutics. The HD market across the 7MM was valued at $0.3 billion in the 2024 baseline year and is projected to grow at a compound annual growth rate (CAGR) of 27.4%, reaching $3.8 billion by 2034. A key driver of growth will be the launch of seven late-stage pipeline products, including the first DMTs for HD.
Report Scope
- Overview of Huntington’s Disease (HD), including epidemiology, symptoms, diagnosis, and disease management.
- Annualized HD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the HD market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for HD. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the 7MM HD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM HD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
- Contents
- Abbreviations
- Related Reports
- Executive Summary
- Disease Overview
- Overview of HD
- Pathophysiology of HD
- Staging Systems of HD
- Huntington’s Disease Integrated Staging System
- HD SWOT Analysis
- Epidemiology
- Diagnosed Incident Cases of Manifest HD, Both Sexes, All Ages, 2024-34
- Age-Specific Trends in Diagnosed Incident Cases of Manifest HD, Both Sexes, 2024
- Sex-Specific Diagnosed Incident Cases of Manifest HD, All Ages, 2024
- Diagnosed Prevalent Cases of All HD (Premanifest and Manifest Combined), Both Sexes, All Ages, 2024-34
- Diagnosed Prevalent Cases of Premanifest HD, Both Sexes, All Ages, 2024-34
- Diagnosed Prevalent Cases of Manifest HD, Both Sexes, All Ages, 2024-34
- Age-Specific Trends in Diagnosed Prevalent Cases of Manifest HD, Both Sexes, 2024
- Sex-Specific Diagnosed Prevalent Cases of Manifest HD, All Ages, 2024
- Diagnosed Prevalent Cases of Manifest HD by Type, All Ages, Both Sexes, 2024
- Diagnosed Prevalent Cases of Adult-Onset Manifest HD by Stage, All Ages, Both Sexes, 2024
- Sources and Methodology for Diagnosed Incident Cases of Manifest HD
- Sources and Methodology for Diagnosed Prevalent Cases of All HD
- Sources and Methodology for Diagnosed Prevalent Cases of Premanifest HD
- Sources and Methodology for Diagnosed Prevalent Cases of Manifest HD
- Sources and Methodology for Manifest HD by Type
- Sources and Methodology for Adult-Onset Manifest HD by Stage
- Sources and Methodology for Diagnosed Incident Cases of Manifest HD
- Sources and Methodology for Diagnosed Prevalent Cases of All HD
- Sources and Methodology for Diagnosed Prevalent Cases of Premanifest HD
- Sources and Methodology for Diagnosed Prevalent Cases of Manifest HD
- Current Treatment Options
- Treatment Paradigm
- Current Treatment Options
- Product Profile: Bausch Health’s Xenazine/Nitoman/Choreazine (tetrabenazine)
- Product Profile: Teva’s Austedo/Austedo XR (deutetrabenzine/deutetrabenzine ER)
- Product Profile: Neurocrine Biosciences’ Ingrezza/Ingrezza Sprinkle (valbenazine)
- Product Profile: Sanofi’s Tiaprizal/Tiapridal/Sereprile/Gramalil (tiapride)
- Patient Flow: HD in 2024 Across 7MM
- Unmet Needs and Opportunities
- Unmet Needs in HD
- Disease-Modifying Therapies
- Early Diagnosis and Consensus on Disease Staging
- Treatment Options for Cognitive and Psychiatric Symptoms
- R&D Strategies
- Trends in Clinical Trial Design in HD
- Trends in Deal-Making in HD
- Pipeline Assessment
- HD Pipeline Overview
- Late-Stage Pipeline Agents for HD
- Product Profile: SOM Biotech’s SOM-3355 (bevantolol hydrochloride)
- Product Profile: Prilenia Therapeutics’ Huntexil (pridopidine)
- Product Profile: Roche’s RG6042 (tominersen)
- Product Profile: Wave Life Sciences’ WVE-003
- Product Profile: uniQure’s AMT-130 (ifezuntirgene inilparvovec)
- Product Profile: PTC Therapeutics/Novartis’s PTC518 (votoplam)
- Product Profile: Skyhawk Therapeutics’ SKY-0515
- HD: Clinical Trials (Phase II/III) Overview
- Market Outlook
- HD Market Forecast
- Market Drivers and Barriers
- Appendix
- Primary Research: KOL Information
- Primary Research: High Prescriber Survey Information
- Bibliography
- About the Authors
- Contact the Publisher
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Teva Pharmaceutical Industries Ltd
- Wave Life Sciences Ltd
- Skyhawk Therapeutics Inc
- Prilenia Therapeutics BV
- Bausch Health
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Neurocrine Biosciences Inc
- PTC Therapeutics Inc
- Sanofi
- Grupo Ferrer Internacional SA
- SOM Biotech SL
- UniQure NV
